Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, Numachi Y, Yoshida R, Peng C, Mikol DD, Lima GPDS, Cheng S. Hirata K, et al. Among authors: imai n. Brain Behav. 2022 Mar;12(3):e2526. doi: 10.1002/brb3.2526. Epub 2022 Feb 24. Brain Behav. 2022. PMID: 35201674 Free PMC article. Clinical Trial.
[New Management of Cluster Headache].
Imai N. Imai N. Brain Nerve. 2021 Apr;73(4):347-355. doi: 10.11477/mf.1416201766. Brain Nerve. 2021. PMID: 33824222 Review. Japanese.
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study.
Suzuki K, Takeshima T, Igarashi H, Imai N, Danno D, Yamamoto T, Nagata E, Haruyama Y, Mitsufuji T, Suzuki S, Ito Y, Shibata M, Kowa H, Kikui S, Shiina T, Okamura M, Tatsumoto M, Hirata K. Suzuki K, et al. Among authors: imai n. J Headache Pain. 2021 Jun 7;22(1):53. doi: 10.1186/s10194-021-01263-1. J Headache Pain. 2021. PMID: 34098873 Free PMC article.
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N. Sakai F, et al. Among authors: imai n. Headache. 2021 Jul;61(7):1102-1111. doi: 10.1111/head.14178. Epub 2021 Jul 29. Headache. 2021. PMID: 34323290 Free PMC article. Clinical Trial.
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R, Numachi Y, Peng C, Mikol DD, Cheng S. Hirata K, et al. Among authors: imai n. J Headache Pain. 2021 Sep 18;22(1):110. doi: 10.1186/s10194-021-01313-8. J Headache Pain. 2021. PMID: 34537006 Free PMC article. Clinical Trial.
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.
Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, Sakurai F, Ning X, Nakai M, Koga N. Hirata K, et al. Among authors: imai n. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):447-454. doi: 10.1080/14740338.2023.2162038. Epub 2022 Dec 28. Expert Opin Drug Saf. 2023. PMID: 36578197
804 results